Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
35 hedge funds and large institutions have $31.2M invested in Orchard Therapeutics plc American Depositary Shares in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 20 closing their positions.
89% more capital invested
Capital invested by funds: $16.5M → $31.2M (+$14.7M)
27% less funds holding
Funds holding: 48 → 35 (-13)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
65% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$6.34M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5.9M |
| 3 |
Citigroup
New York
|
+$912K |
| 4 |
KI
Kapitalo Investimentos
Sao Paulo,
Brazil
|
+$779K |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$648K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.46M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$816K |
| 3 |
AG
Artal Group
Luxembourg
|
-$669K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$577K |
| 5 |
Renaissance Technologies
New York
|
-$506K |
ORTX Hedge Fund Activity: Q1 2023 in Review
35 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q1 2023, worth a combined $31.2M — up 89% from $16.5M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ORTX and 7 opened new positions — a net loss of 13 holders — while 13 trimmed existing stakes and 9 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $6.34M. The largest seller was Fidelity Investments, cutting an estimated $4.46M.
- 35 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q1 2023, down from 48 in Q4 2022.
- Funds reported $31.2M of Orchard Therapeutics plc American Depositary Shares stock for Q1 2023, up 89% quarter-over-quarter.
- 7 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q1 2023 and 20 closed out, a net change of -13 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q1 2023 was Deep Track Capital, an estimated $6.34M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q1 2023 was Fidelity Investments, an estimated $4.46M sold.
Based on aggregated 13F filings for Q1 2023.